<DOC>
	<DOCNO>NCT00377559</DOCNO>
	<brief_summary>This open phase II multicentre study evaluate efficacy safety non pegylated liposomal doxorubicin ( Myocet® ) docetaxel ( Taxotere® ) combination first-line treatment patient metastatic HER2/neu negative breast cancer .</brief_summary>
	<brief_title>Liposomal Doxorubicin Docetaxel HER2 Negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Phase II non comparative study , assess safety ( primarily cardiac safety ) efficacy patient locally advance metastatic HER2/neu negative breast cancer yet treat chemotherapy metastatic disease . Myocet Taxotere give maximum 6 cycle . Endpoints : cardiotoxicity ( left ventricular ejection fraction decrease and/or symptom heart failure ) , serious toxicity , disease progression .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Women histologically document metastatic locally advanced metastatic HER2/neu negative breast cancer . In case previous adjuvant neoadjuvant chemotherapy anthracyclines taxanes , must complete 12 month inclusion . In case previous adjuvant neoadjuvant chemotherapy , cumulative anthracycline dose ≤ 360 mg/m2 doxorubicin 600 mg/m2 epirubicin 75 mg/m2 mitoxantrone inclusion . Previous endocrine therapy authorize ( endocrine therapy goserelin must stop start treatment ) . Previous radiotherapy authorize , discontinue ≥ 4 week prior inclusion study &lt; 10 % bone marrow within irradiated area . Age ≥ 18 year . Performance status 0,1 , 2 . Life expectancy ≥ 3 month . Evaluable disease . Normal LVEF ( multigated acquisition [ MUGA ] scan echocardiography ) . Normal haematological , hepatic renal parameter : neutrophil ≥ 1.5 x 10^9/l ; platelet ≥ 100 x 10^9/l ; hemoglobin ( Hb ) ≥ 6 mmol/L ; total bilirubin ≤ 1.5 time upper limit normal ( ULN ) ; transaminases ≤ 2.5 x ULN ; alkaline phosphatase ≤ 2.5 x ULN ; creatinine ≤ 1.5 x ULN . Dated sign write informed consent . Previous chemotherapy metastatic disease . History cancer , except cervical carcinoma situ treat cone resection basal cell squamous cell skin cancer . History congestive heart failure myocardial infarction ≤ 1 year ; cardiac function : NYHA ≥ 2 LVEF &lt; 50 % . Uncontrolled significant heart disease , unstable angina . Poorly control hypertension . Performance status 3 , 4 . Symptomatic progressive brain metastasis . Active infection serious underlying disease . Concomitant participation clinical trial . Pregnant woman nurse mother ; patient childbearing potential without effective contraception . Absolute medical contraindication use corticosteroid premedication . Allergy polysorbate 80 , doxorubicin , egg lecithin . NCICTC grade &gt; 1 peripheral neuropathy . Patients able comply regular medical followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>cardiotoxicity</keyword>
	<keyword>liposomal</keyword>
	<keyword>doxorubicin</keyword>
	<keyword>docetaxel</keyword>
	<keyword>HER2/neu negative metastatic breast cancer</keyword>
</DOC>